ABT Abbott Laboratories
Company Analysis
Latest News
Abbott Laboratories stock little changed as market closed for MLK Day; Tariff concerns weigh on healthcare sector
Abbott Laboratories (ABT) fell 1.43% to close at $121.76 following the announcement of 10% tariffs on eight European nations, creating significant geopolitical...
Abbott's FreeStyle Libre 3 Plus Gains Nationwide Public Funding in Canada
Abbott Laboratories announced that its FreeStyle Libre 3 Plus sensor has secured broad public funding across all Canadian provinces, significantly expanding...
Abbott Laboratories gains momentum on AI diabetes platform and analyst upgrades ahead of Q4 earnings
Abbott Laboratories (ABT) received positive analyst sentiment, including a price target increase to $169 from Barclays, following the showcase of its new...
Abbott Launches AI-Powered Libre Assist Feature for Diabetes Management at CES 2026
Abbott launched Libre Assist, a new feature integrated into its Libre mobile app. The tool is designed to help people with diabetes understand the potential...
Abbott Laboratories Eyes 2026 with Strategic Focus on Biowearables and Metabolic Health
Abbott Laboratories enters 2026 strategically focused on metabolic health and consumer-facing biowearables, exemplified by its Lingo platform and planned...
Abbott Laboratories Boosts Dividend 7% and Sees Legal Alert Withdrawn for Exact Sciences Acquisition
Abbott Laboratories delivered positive news, notably announcing a 7% dividend increase, raising its quarterly payout to $0.63. This move, highlighted earlier...
Abbott Faces Product Safety Crisis Amid New Device Approval
Abbott Laboratories faces a critical product safety issue following an FDA report on December 23, 2025, linking its Freestyle Libre Plus Continuous Glucose...
Abbott Secures FDA Approval for Volt PFA System to Treat Atrial Fibrillation
On December 22, Abbott Laboratories received FDA approval for its Volt™ Pulsed Field Ablation (PFA) System, designed to treat atrial fibrillation (AFib). This...